This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Xibo Li, Ph.D.
Associate Director, Oligonucleotide Process Development at LGC


Xibo is Director of Oligonucleotide Chemistry of LGC Axolabs in Petaluma, CA. He earned his Ph.D. in Organic Chemistry with a focus on nucleic acid chemistry from the University of Utah under the guidance of Prof. Cynthia Burrows.

Xibo began his industrial career in 2015 at Covance Salt Lake City focusing on bioanalysis method development using LC-MS. He later joined Nitto Denko Avecia to start his oligo manufacturing career at Cincinnati site and grew with increasing responsibilities within the organization and has successfully led many process development projects and overseen the technical transfer to the production team. In 2018, he joined LGC Group in Petaluma, CA to build the oligonucleotide therapeutic CDMO business unit from scratch as head of Oligonucleotide Therapeutic Process Development and Production.

Agenda Sessions

  • LGC’s Approach to Tackle a Complex Aptamer Manufacture: A Case Study